Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity

• Hoofdauteurs: Massimiliano Scalvenzi (Auteur), Milena Cappello (Auteur), Claudia Costa (Auteur), Gabriella Fabbrocini (Auteur), Mariaantonietta Luciano (Auteur), Alessia Villani (Auteur)
• Formaat: Boek
• Gepubliceerd in: Adis, Springer Healthcare, 2020-04-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Abstract Introduction Locally advanced basal cell carcinoma (laBCC) has always represented an uncommon, difficult-to-treat form of skin cancer, but approval of the Hedgehog inhibitor (HHI) vismodegib has provided an effective, well-tolerated therapy. While this drug has been shown to be a safe and e...